urotoli

urTierTqmedeba sxva samkurnalo saSualebebTan
moerideT tolterodinis erTdroulad miRebas CYP3A4 Zlieri inhibitorebTan,
magaliTad, makrolidur antibiotikebTan (eriTromicini, klariTromicini),
sokos sawinaaRmdego saSualebebTan (ketokonazoli, itrakonazoli da
mikonazoli), proteazis inhibitorebTan sisxlis SratSi tolterodinis
koncentraciis momatebis SesaZleblobis gamo, rac zrdis preparatis dozis
gadaWarbebis risks.
muskarinuli qolinerguli receptorebis agonistebi aqveiTebs tolterodinis
efeqturobas.
antiqolinerguli Tvisebebis mqone samkurnalo sasualebebi aZlierebs
gverdiTi movlenebis moqmedebas da zrdis maTi ganviTarebis risks.
preparati asustebs prokinetikebis (metoklopramidi, cizapridi) moqmedebas.
SesaZlebelia farmakokinetikuri urTierTqmedeba preparatebdan, romlebic
metabolizdeba citoqroma P450 CYP2D6 an CYP3A4 izofermentebiT
(induqtorebiT da inhibitorebiT).
fluoqsetinTan (CYP2D6 Zlieri inhibitori - metabolizdeba
norfluoqsetinamde, romelic warmoadgens CYP3A4 inhibitors) erTdroulad
miReba iwvevs tolterodinisa da misi aqtiuri 5-hidroqsimeTiluri
metabolitis saerTo AUC mxolod umniSvnelo momatebas, rac ar iwvevs
klinikurad mniSvnelovan urTierTqmedebas.
ar arsebobs urTierTqmedeba varfarinTan da kombinirebul peroralur
kontraceptivebTan (romlebic Seicavs eTinilestradiols/levonorgestrels).
tolterodini ar warmoadgens CYP2D6, 2C19, 3A4, 1A2 inhibitors, amitom
tolterodinTan kombinaciaSia miRebisas mosalodneli ar aris sisxlis
plazmaSi im preparatebis donis momateba, romlebic metabolizdeba mocemuli
izofermentebiT.
gansakuTrebuli miTiTeba
mkurnalobis dawyebamde saWiroa gamoiricxos moSardvis xSiri da
imperatiuli survilis organuli mizezebi.
reproduqciuli asakis qalebSi mkurnalobis dawyeba SeiZleba mxolod
saimedo kontracepciis gamoyenebis pirobiT.
6